Allarity Therapeutics closed at $1.08 on Nov 4, down 4.42%, 39.0% below its 52-week closing high. Volume of 136.1K shares was 0.90× its 20-day average (close to normal).
Split-adjusted performance: +9.6% over one month, -27.0% over six months, -21.7% over one year.
Short interest was 168.0K shares at the Oct 15 settlement, up 41.0% from the prior report (1.1% of float, 1.4 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| ALLRAllarity Therapeutics | $1.08 | −4.42% | −27.0% | — | — | — | $17.2M | |
| MRKRMarker Therapeutics | $1.01 | +2.76% | −30.8% | — | — | — | $16.8M | Compare |
| KTTAPasithea Therapeutics | $0.5300 | 0.00% | −37.6% | — | — | — | $17.7M | Compare |
| MTEXMannatech | $8.64 | −0.06% | +77.0% | +3.8% | 3.8% | — | $16.7M | Compare |
| NEUPNeuphoria Therapeutics | $2.98 | −0.33% | −44.6% | — | — | — | $16.1M | Compare |
| KYNBKyntra Bio | $3.96 | −8.12% | −44.4% | — | — | — | $16.0M | Compare |
| CNTXContext Therapeutics | $0.2035 | +4.90% | −91.6% | — | — | — | $18.7M | Compare |
| BOLTBolt Biotherapeutics | $6.54 | −0.46% | +42.5% | −99.7% | −154400.0% | — | $15.4M | Compare |
| COCPCocrystal Pharma | $1.01 | −5.61% | −28.4% | — | −3013.3% | — | $19.5M | Compare |
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
